| Name | Title | Contact Details |
|---|
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide, with more than 100,000 implanted to date.
Evalve Inc is a Menlo Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Novarix is a collaborative medical device development company based near Oxford, UK and Raleigh, North Carolina, USA, delivering innovative new products in the field of venepuncture and cannulation to the worldwide healthcare sector. Novarix are proud to bring to market the IV-eye® – a portable, near infrared (NIR) vein imaging device which demonstrates the company ethos of practicality, simplicity and performance for both healthcare professionals and patients. The product idea came from a nursing perspective and has been developed in consultation with medical professionals in the UK and Denmark and with assistance from the biomedical engineering departments of Oxford University and University College London.
At T2 Biosystems, we are united in our mission: to improve patient outcomes, lower mortality rates and reduce the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. By leveraging the power of our innovative and proprietary T2 Magnetic Resonance (T2MR) platform, T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies. T2 Biosystems is currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. Our T2Candida Panel tackles sepsis and is the first FDA-cleared diagnostic panel requiring no blood culture – delivering more accurate results in hours versus days. Other ongoing development efforts include bacterial and hemostasis panels, as well as a Lyme disease partnership with Canon Life Sciences. Over 100 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications, including the direct detection and measurement of targets in various sample types, such as whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of diagnostics.
Digirad Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.